Is telehealth allowed to prescribe Wegovy in California?

If you’ve been researching weight loss options, you’ve likely heard about breakthrough medications like Wegovy, Ozempic, and Mounjaro. These GLP-1 medications have transformed obesity treatment—and the rise of telehealth has made them more accessible than ever. But can you legally get these prescriptions online? What are the rules in your state? And how do you know if a telehealth provider is legitimate?

This comprehensive guide answers all your questions about getting GLP-1 weight loss medications through telehealth, including state-specific regulations, provider qualifications, and what to expect from your virtual visit.

The Short Answer: Yes, Telehealth Prescribing of GLP-1 Medications Is Legal

Here’s what you need to know right away: You can legally obtain GLP-1 weight loss medications like Wegovy, Ozempic, or Mounjaro through telehealth in the United States. Because these medications are not controlled substances, federal law does not require an in-person visit before prescribing them.

This is fundamentally different from medications like Adderall or other controlled substances, which have historically required face-to-face consultations under the Ryan Haight Act. GLP-1 medications for weight loss fall outside these restrictions, making telehealth a fully viable—and increasingly popular—option for patients seeking treatment.

During the COVID-19 pandemic, telehealth regulations were relaxed across the board. As of late 2025, those flexibilities for controlled medications remain in effect through December 31, 2025, with strong indications of further extensions. For non-controlled medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), telehealth prescribing has remained consistently available.

What this means for you: A licensed healthcare provider can evaluate you through a video consultation, review your medical history and weight loss goals, and electronically send a prescription to your pharmacy—all without requiring you to visit a physical clinic.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Understanding GLP-1 Medications for Weight Loss

Before diving into telehealth regulations, let’s clarify what these medications are and how they work.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) agonists are injectable medications that mimic a hormone your body naturally produces to regulate blood sugar and appetite. Originally developed for type 2 diabetes, these medications have proven remarkably effective for weight management.

The three main GLP-1 medications prescribed for weight loss are:

• Wegovy (semaglutide 2.4mg): FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition
• Ozempic (semaglutide 0.5-1mg): FDA-approved for type 2 diabetes but frequently prescribed off-label for weight loss
• Mounjaro (tirzepatide): FDA-approved for type 2 diabetes; a higher-dose version called Zepbound is approved for obesity

How Do They Work?

These medications work through several mechanisms:

• Appetite suppression: They signal fullness to your brain, reducing hunger and cravings
• Slower gastric emptying: Food stays in your stomach longer, helping you feel satisfied with smaller portions
• Blood sugar regulation: They help stabilize glucose levels, reducing insulin resistance

Patients typically lose 10-20% of their body weight over several months when combining these medications with lifestyle modifications.

Who Qualifies for Treatment?

Reputable telehealth providers follow FDA guidelines for prescribing these medications. You generally qualify if you:

• Have a BMI of 30 or higher (obesity), OR
• Have a BMI of 27 or higher with at least one weight-related condition (such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea)
• Have attempted lifestyle modifications (diet and exercise) without achieving adequate weight loss
• Do not have contraindications (discussed below)

Important contraindications include:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning to become pregnant
• Active gallbladder disease or history of pancreatitis
• Severe gastrointestinal disorders like gastroparesis
• History of severe allergic reactions to semaglutide or tirzepatide

Federal Regulations: The Foundation for Telehealth Prescribing

Understanding federal law helps explain why telehealth prescribing of GLP-1 medications is so straightforward compared to other prescriptions.

The Ryan Haight Act and Why It Doesn’t Apply

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires an in-person medical evaluation before prescribing controlled substances via telemedicine. This law was designed to prevent online ‘pill mills’ from dispensing opioids and other addictive medications without proper oversight.

However, GLP-1 medications are not controlled substances. The Ryan Haight Act’s in-person examination requirement simply doesn’t apply to them. This means:

• No federal mandate for an initial in-person visit
• No restrictions on prescription quantity based on telehealth status
• No special DEA registration required (beyond standard prescribing authority)

Current COVID-Era Flexibilities

While GLP-1 prescribing wasn’t affected by pre-pandemic restrictions, it’s worth noting the broader telehealth landscape. The Drug Enforcement Administration (DEA) has extended pandemic-era telehealth flexibilities for controlled substances through December 31, 2025. This extension allows medications like Adderall and buprenorphine to be prescribed via telehealth without an initial in-person exam.

A proposed fourth extension is expected in 2026, and Congress is considering the TREATS Act, which would make certain telehealth prescribing flexibilities permanent. This indicates strong federal support for expanding telehealth access across all medication classes.

FDA Oversight and Compounding

In 2025, the FDA took significant action regarding GLP-1 medications. After declaring the Wegovy and Ozempic shortage resolved, the agency ended emergency allowances for compounding semaglutide. As of May 2025, routine retail compounding of semaglutide for weight loss is effectively banned.

This action protects patients from potentially unsafe or ineffective compounded versions while ensuring quality through FDA-approved, manufacturer-produced medications. Legitimate telehealth providers now prescribe only FDA-approved branded medications dispensed through licensed pharmacies.

State-by-State Telehealth Regulations

While federal law permits telehealth prescribing of GLP-1 medications, states add their own requirements. These variations create a patchwork of rules that telehealth providers must navigate carefully.

States Requiring an Initial In-Person Exam

Several states mandate that patients complete an in-person physical examination before or shortly after starting weight loss medication therapy via telehealth:

Arkansas: Among the most restrictive states for telemedicine, Arkansas requires an initial in-person encounter to establish a valid patient-provider relationship. The state medical board has proposed easing these restrictions, but as of late 2025, the in-person requirement remains.

Delaware: Requires an initial physical examination in person before prescribing weight loss medications through telehealth. Follow-up visits can be conducted virtually.

Georgia: State obesity treatment policy requires an initial in-person evaluation before telehealth prescribing of weight loss medications. However, Georgia recently expanded prescriptive authority for nurse practitioners and physician assistants, making care more accessible.

Mississippi: State law requires an initial in-person evaluation for weight management therapy, though ongoing advocacy aims to expand telehealth access.

New Jersey: Perhaps the strictest state, New Jersey requires a comprehensive initial in-person examination including detailed medical history, physical exam, laboratory tests, and psychological screening before prescribing any weight loss medication.

North Dakota: Expects a hands-on initial evaluation for weight loss treatment per state medical board guidance, though the state generally embraces telehealth.

South Carolina: Requires an initial in-person visit and periodic evaluations for obesity treatment.

Texas: While Texas generally allows telehealth, the standard of care typically requires an initial in-person exam for weight loss medication prescribing. Texas also has strict oversight of nurse practitioner prescribing authority.

States With Comprehensive Treatment Requirements

Some states allow telehealth prescribing but mandate specific treatment protocols:

Connecticut: Permits telehealth prescribing but requires that obesity treatment include behavioral counseling and a documented diet and exercise plan alongside medication.

Florida: Allows telehealth prescribing for patients with BMI ≥30 and mandates follow-up visits at least every three months during active treatment. No in-person requirement for the initial visit.

Virginia: Requires an initial comprehensive work-up including physical examination, laboratory tests, and a personalized diet and exercise plan. A follow-up visit must occur within 30 days of starting therapy. After meeting these requirements, ongoing telehealth management is permitted.

States With Minimal Telehealth Restrictions

Many states have embraced telehealth without imposing special requirements for weight loss medications:

California, Illinois, New York, Pennsylvania, Utah, Washington: These states permit telehealth prescribing of GLP-1 medications with a standard of care equivalent to in-person treatment. A comprehensive medical evaluation via video consultation is sufficient to establish the patient-provider relationship and initiate treatment.

These states generally have more progressive telehealth policies, recognizing that virtual care can meet the same quality standards as traditional office visits when conducted properly.

Understanding ‘Initial Only’ vs. ‘Never’ Requirements

In our state-by-state table above, you’ll see terms like:

• ‘Never’: No in-person examination required at any point—telehealth suffices for the entire treatment journey
• ‘Initial Only’: First evaluation must be in-person, but follow-ups can be virtual
• ‘Periodic (X months)’: In-person exams required at specified intervals (rare for GLP-1s)

These distinctions matter when choosing a telehealth provider. If you live in an ‘Initial Only’ state, you may need to visit a local clinic for baseline measurements and labs before your telehealth provider can prescribe medication.

Provider Qualifications: Who Can Prescribe?

Not all healthcare providers have the same prescribing authority. Understanding who can prescribe GLP-1 medications in your state helps set proper expectations for your telehealth experience.

Physicians (MD/DO)

Medical doctors and doctors of osteopathic medicine can prescribe GLP-1 weight loss medications in all states, provided they’re licensed in the state where the patient is physically located during the telehealth visit. This is the most straightforward scenario—if your telehealth provider is an MD or DO licensed in your state, there are no additional barriers.

Nurse Practitioners (NPs)

Nurse practitioner prescribing authority varies significantly by state:

Full Practice Authority (34 states + DC): In these states, NPs can evaluate patients, diagnose conditions, and prescribe medications independently without physician oversight. States with full NP independence include:

• Arizona, Alaska, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Dakota, Oregon, Rhode Island, South Dakota, Utah, Vermont, Washington, Wisconsin, Wyoming, and Washington DC

Reduced Practice Authority: Some states require NPs to have a collaborative agreement or protocol with a physician but allow substantial independence in prescribing. Examples include Florida, Georgia, Illinois, and Pennsylvania.

Restricted Practice Authority: A few states require physician supervision for all NP activities. Texas is notable for maintaining relatively strict supervision requirements—Texas NPs must have a physician delegation agreement and cannot prescribe certain controlled substances even with physician oversight (though GLP-1s are unaffected).

What this means for patients: You may work with an NP through your telehealth provider, especially in states with full practice authority. This is completely legitimate and legal. Klarity Health, for example, employs both physicians and nurse practitioners, ensuring appropriate credentials for each state’s requirements.

Physician Assistants (PAs)

Physician assistants typically practice under collaborative agreements with physicians. Their prescribing authority for weight loss medications is generally similar to NPs in reduced-practice states. All states allow PAs to prescribe non-controlled medications like GLP-1s with appropriate physician collaboration.

What to Expect From a Legitimate Telehealth Visit

Understanding the telehealth process helps you identify reputable providers and know what constitutes appropriate care.

Initial Consultation

A proper telehealth weight loss evaluation should include:

1. Comprehensive Medical History

• Current medications and supplements
• Past medical conditions and surgeries
• Family history of thyroid cancer or MEN2
• Previous weight loss attempts and results
• Mental health history and eating disorder screening

2. Detailed Lifestyle Assessment

• Current diet and exercise habits
• Sleep patterns and stress levels
• Weight loss goals and motivation
• Barriers to previous weight loss success

3. Vital Signs and Measurements

• Current height and weight (self-reported, often with photo verification)
• BMI calculation
• Blood pressure (if available from home monitor)
• Recent lab results if available

4. Video ConsultationMost states and best practices require a live, two-way video interaction between provider and patient. This allows the provider to:

• Verify your identity
• Assess your overall health and wellbeing
• Discuss treatment options and alternatives
• Answer your questions in real-time
• Obtain informed consent for treatment

5. Risk Assessment and Contraindication ScreeningThe provider will specifically ask about conditions that would make GLP-1 therapy unsafe:

• Thyroid cancer history (personal or family)
• Pregnancy status and plans
• Gallbladder or pancreas problems
• Severe gastrointestinal issues
• Kidney disease

Informed Consent Process

Before prescribing, your provider should clearly explain:

Benefits:

• Expected weight loss (typically 10-20% of body weight over 6-12 months)
• Improvements in obesity-related conditions
• Long-term health benefits of sustained weight loss

Risks and Side Effects:

• Common GI side effects: nausea, diarrhea, constipation, vomiting
• Risk of gallstones with rapid weight loss
• Rare but serious risks: pancreatitis, thyroid tumors (in animal studies)
• Medication interactions

Alternatives:

• Lifestyle modification alone
• Other weight loss medications
• Bariatric surgery for severe obesity
• Combination approaches

Costs:

• Medication cost (insurance coverage vs. out-of-pocket)
• Consultation fees
• Follow-up visit costs

Many states explicitly require documented informed consent specific to weight-loss drug therapy. Your provider should have you sign a consent form acknowledging you understand the risks and benefits.

Treatment Plan Development

If you’re deemed appropriate for GLP-1 therapy, your provider will create a comprehensive treatment plan including:

Medication Regimen:

• Starting dose (usually the lowest dose to minimize side effects)
• Titration schedule (gradual dose increases every 4 weeks)
• Administration instructions (proper injection technique)
• What to do if you miss a dose

Lifestyle Modifications:

• Calorie targets and nutrition guidance
• Exercise recommendations (type, frequency, duration)
• Behavioral strategies for eating habits
• Sleep and stress management

Monitoring Plan:

• Follow-up schedule (typically monthly initially, then every 2-3 months)
• Lab work as needed (metabolic panel, A1C if diabetic)
• Weight tracking expectations
• When to contact the provider

Safety Protocols:

• Warning signs requiring immediate medical attention
• How to report side effects
• Emergency contact information

Follow-Up Care

Ongoing monitoring is essential for safe and effective treatment:

Initial Follow-Up (1 month):

• Assess tolerance of medication
• Review side effects and management strategies
• Confirm weight loss is occurring
• Adjust dose if appropriate
• Reinforce lifestyle modifications

Ongoing Follow-Ups (Every 2-3 months):

• Track cumulative weight loss
• Monitor for adverse effects
• Adjust medication dose toward target
• Review and refine lifestyle plan
• Assess motivation and adherence

State-Mandated Follow-Ups:Remember that Florida requires visits at least every 3 months, Virginia mandates a 30-day check-in, and several states have similar requirements. Reputable telehealth providers build these requirements into their programs automatically.

Cost Considerations: Insurance vs. Cash Pay

Understanding the financial aspects of telehealth weight loss treatment helps you plan accordingly.

Insurance Coverage

Coverage Varies Widely:

• Many insurance plans now cover GLP-1 medications for obesity (not just diabetes)
• Coverage requirements often include documented BMI ≥30 or ≥27 with comorbidities
• Some plans require prior authorization and proof of lifestyle modification attempts
• Copays can range from $25 to several hundred dollars monthly

Medicare:

• Traditional Medicare Part D does not cover medications prescribed solely for weight loss
• Medicare Advantage plans may offer coverage (check your specific plan)
• Medicare does cover obesity counseling services

Medicaid:

• Coverage varies by state
• Some states cover GLP-1s for obesity; others limit coverage to diabetes only

Cash Pay Options

For those without insurance coverage or facing high out-of-pocket costs:

Manufacturer Savings Programs:

• Novo Nordisk offers savings cards for Wegovy (up to $500-$1,400 off monthly)
• Eli Lilly provides savings options for Mounjaro/Zepbound
• Eligibility restrictions apply (typically for commercially insured patients, not government insurance)

Telehealth Provider Pricing:

• Some telehealth platforms offer bundled pricing (consultation + medication)
• Monthly programs typically range from $200-$500 including medication
• Klarity Health accepts both insurance and cash pay, with transparent pricing that helps patients understand their total costs upfront

Pharmacy Shopping:

• Prices vary significantly between pharmacies
• Online pharmacies and mail-order services may offer lower prices
• Use pharmacy discount cards (GoodRx, SingleCare) if paying cash

Hidden Costs to Consider

Lab Work:Some providers require periodic laboratory monitoring (metabolic panel, liver function tests). These may be billed separately.

Follow-Up Visits:While initial consultations are clearly priced, confirm the cost of follow-up appointments. Some platforms charge per visit; others offer monthly subscriptions.

Supplies:While the medication typically includes needles, you may need alcohol swabs, sharps containers, and other injection supplies.

Red Flags: How to Spot Illegitimate Telehealth Services

The popularity of GLP-1 medications has unfortunately attracted bad actors. Protect yourself by watching for these warning signs:

Prescription Guarantees

Red Flag: Any service that guarantees you’ll receive a prescription before evaluation.

Why It’s Problematic: Legitimate medical practice requires individualized assessment. Not everyone qualifies for GLP-1 therapy, and promising a prescription upfront indicates the provider isn’t conducting proper evaluations.

What to Look For Instead: Services that clearly state prescription is based on medical eligibility and provider judgment.

Compounded or ‘Generic’ Semaglutide

Red Flag: Offers for compounded, ‘generic,’ or imported versions of Wegovy/Ozempic at dramatically reduced prices.

Why It’s Problematic: As of May 2025, the FDA banned routine compounding of semaglutide for weight loss due to safety and quality concerns. True generic versions don’t exist yet (patents haven’t expired). Imported medications may be counterfeit or improperly stored.

What to Look For Instead: FDA-approved branded medications (Wegovy, Ozempic, Mounjaro, Zepbound) dispensed through licensed U.S. pharmacies.

Minimal Medical Evaluation

Red Flag: Services that don’t require a live video consultation or accept only a brief questionnaire.

Why It’s Problematic: Proper evaluation requires real-time interaction to assess appropriateness, screen for contraindications, and establish a genuine patient-provider relationship. Many states explicitly require synchronous (live) video for prescribing.

What to Look For Instead: Mandatory video consultations with licensed providers, comprehensive health questionnaires, and thorough screening processes.

No Follow-Up or Monitoring

Red Flag: Services that prescribe medication without scheduling follow-up appointments or monitoring progress.

Why It’s Problematic: GLP-1 medications require ongoing monitoring for safety and efficacy. Dose adjustments, side effect management, and long-term planning are essential components of treatment. Some states legally mandate regular follow-ups.

What to Look For Instead: Clear follow-up schedules, accessible provider communication, and emphasis on long-term monitoring.

Unclear Provider Credentials

Red Flag: Inability to verify provider licenses or reluctance to share provider information before consultation.

Why It’s Problematic: Providers must be licensed in your state. Legitimate services proudly display provider credentials and make license verification easy.

What to Look For Instead: Clear information about who will provide your care, their credentials (MD, DO, NP), and their state licenses. You should be able to verify licenses through state medical or nursing board websites.

No Physical Address or Phone Contact

Red Flag: Online-only services with no physical address, phone number, or identifiable business location.

Why It’s Problematic: Legitimate healthcare providers maintain verifiable business addresses and multiple contact methods. This is both a legal requirement and a red flag for potential scams.

What to Look For Instead: Complete contact information including phone support, business address, and clear ownership/affiliation information.

Pressure Tactics or Aggressive Marketing

Red Flag: High-pressure sales tactics, ‘limited time offers,’ or urgent messaging to start treatment immediately.

Why It’s Problematic: Medical decisions should never be rushed. Ethical providers give patients time to consider options, ask questions, and make informed choices.

What to Look For Instead: Patient-centered communication, no pressure to start treatment, and emphasis on informed decision-making.

The Klarity Health Approach to Telehealth Weight Loss

At Klarity Health, we’re committed to making legitimate, safe, and effective weight loss treatment accessible through telehealth while maintaining the highest standards of care.

Our Core Principles

Provider Excellence:We work exclusively with licensed physicians and nurse practitioners who are credentialed in each state we serve. Our providers receive ongoing training in obesity medicine and telehealth best practices.

Comprehensive Evaluation:Every patient completes a thorough medical history and participates in a live video consultation. We screen carefully for contraindications and ensure GLP-1 therapy is appropriate for your situation.

Transparent Pricing:We accept both insurance and cash pay options with clear, upfront pricing. You’ll know your costs before committing to treatment—no surprise bills.

State Compliance:Our clinical protocols comply with regulations in every state where we operate. If your state requires an initial in-person exam, we’ll coordinate with local providers to ensure you meet that requirement before prescribing.

Ongoing Support:Treatment doesn’t end with a prescription. We provide regular follow-ups, medication management, lifestyle counseling, and responsive communication when questions or concerns arise.

Evidence-Based Care:We prescribe only FDA-approved medications and follow established clinical guidelines for obesity treatment. Our approach combines medication with lifestyle modification for optimal, sustainable results.

Why Access Matters

Obesity is a chronic medical condition affecting more than 40% of American adults. Yet access to effective treatment has been limited by:

• Geographic barriers (specialists concentrated in urban areas)
• Time constraints (difficulty scheduling office visits)
• Stigma around seeking weight loss treatment
• High costs and limited insurance coverage

Telehealth breaks down many of these barriers. By expanding access to qualified providers, transparent pricing, and convenient care delivery, services like Klarity Health make evidence-based weight loss treatment available to people who might otherwise go without.

Looking Ahead: The Future of Telehealth Weight Loss Treatment

The regulatory landscape continues to evolve, generally in a direction that expands and stabilizes telehealth access.

Federal Developments

DEA Telehealth Rules:While current flexibilities for controlled substance prescribing expire December 31, 2025, strong signals indicate another extension or new permanent rules. The TREATS Act, if passed, would codify certain telehealth prescribing flexibilities permanently.

Congressional Support:Bipartisan support for telehealth is strong. The COVID-19 pandemic demonstrated that virtual care can be safe, effective, and convenient. Legislators recognize the value of maintaining expanded access.

Medicare Changes:Medicare telehealth coverage has expanded significantly and may continue to broaden, potentially including coverage for anti-obesity medications in the future.

State Trends

NP Practice Authority:The trend toward full practice authority for nurse practitioners continues. As more states grant independence, telehealth services can leverage NP expertise more effectively, increasing access.

Interstate Licensure Compacts:More states are joining compacts that allow providers to practice across state lines more easily, reducing barriers for multi-state telehealth services.

Telehealth-Specific Regulations:Rather than restrictive rules, most states are developing thoughtful telehealth regulations that balance access with patient safety—establishing standards for patient-provider relationships, appropriate technology, and documentation requirements.

Technology Innovations

Remote Monitoring:Integration of wearable devices, connected scales, and continuous glucose monitors provides real-time data to support telehealth management of obesity.

AI-Enhanced Support:Artificial intelligence tools are beginning to offer personalized nutrition planning, behavior change support, and predictive analytics to optimize treatment—though always under human provider oversight.

Integrated Platforms:Comprehensive platforms that combine telehealth consultations, prescription management, pharmacy coordination, lifestyle tracking, and peer support create seamless patient experiences.

Frequently Asked Questions

Can I use telehealth if my state requires an initial in-person visit?

Yes, but you’ll need to coordinate an in-person examination with a local provider first. Some telehealth services can help arrange this; others require you to obtain the exam independently and provide documentation before they can prescribe. Once the initial in-person requirement is met, follow-up care can typically proceed virtually.

Will my insurance cover telehealth weight loss treatment?

Coverage depends on your specific plan. Many insurers now cover GLP-1 medications prescribed via telehealth the same as in-person prescriptions, but some require prior authorization or specific criteria. Contact your insurance company to verify coverage, or work with a service like Klarity Health that can verify benefits for you.

How quickly can I get started?

If you live in a state without an initial in-person requirement, you can typically complete your consultation and receive a prescription within a few days. Pharmacy fulfillment adds another few days. The medication itself may take 1-2 weeks to show effects, with gradual dose increases over several months to reach your target dose.

What if I experience side effects?

Your telehealth provider should be accessible for questions and concerns. Common side effects like nausea often improve with dose adjustments or symptomatic treatment. Severe side effects require immediate medical attention—your provider will give you clear guidelines about when to seek emergency care.

Can I switch from in-person to telehealth care (or vice versa)?

Yes. If you’re currently seeing a provider in person and want to switch to telehealth, or you’re using telehealth and prefer in-person care, transitions are possible. Medical records can be transferred, and your new provider will review your treatment history before continuing care.

Are telehealth prescriptions more expensive than in-person?

Not necessarily. Consultation fees for telehealth are often lower than traditional office visits. Medication costs are the same regardless of where it was prescribed. The total cost depends on your insurance coverage, the specific service you use, and whether you qualify for manufacturer savings programs.

Do I need special equipment for a telehealth visit?

Just a smartphone, tablet, or computer with camera and internet connection. Most platforms use simple video calling technology that doesn’t require special software downloads. A quiet, private space for your consultation is helpful but not required.

Can I get refills without another video visit?

This depends on your state’s regulations and your provider’s protocols. Many states and providers allow prescription refills after asynchronous check-ins (messaging) if you’re doing well on a stable dose. However, periodic video follow-ups are typically required for ongoing prescribing—often every 2-3 months.

Take the Next Step Toward Your Weight Loss Goals

If you’ve struggled with weight loss through diet and exercise alone, GLP-1 medications may offer the breakthrough you need—and telehealth makes accessing this treatment more convenient than ever.

Getting started is straightforward:

1. Research your state’s requirements using the comprehensive table in this guide
2. Choose a reputable telehealth provider that employs licensed clinicians in your state and follows evidence-based protocols
3. Complete a thorough medical evaluation including health history and video consultation
4. Work with your provider to develop a comprehensive treatment plan combining medication with lifestyle changes
5. Stay engaged with regular follow-ups and honest communication about your progress

At Klarity Health, we make this process seamless. Our platform connects you with licensed providers who specialize in weight management, offers transparent pricing for both insured and self-pay patients, and provides ongoing support throughout your weight loss journey.

Telehealth has revolutionized access to obesity treatment. With proper medical oversight, FDA-approved medications, and commitment to lifestyle change, sustainable weight loss is within reach—no matter where you live.

Ready to explore your options? Klarity Health is here to help you navigate telehealth weight loss treatment with confidence, compassion, and clinical excellence.

Research Citations

1. DEA and HHS Extend Telemedicine Flexibilities Through 2025 – Official DEA announcement regarding the extension of pandemic-era telehealth prescribing rules for controlled substances. U.S. Drug Enforcement Administration, November 15, 2024.

2. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – Legal analysis of DEA’s third extension and the ongoing status of permanent telemedicine regulations. McDermott Will & Emery, November 18, 2024.

3. The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Comprehensive overview of state-specific prescribing requirements for obesity medications including Florida, New Jersey, and Virginia regulations. Goodwin Procter LLP, March 27, 2024.

4. COVID-Era Telehealth Prescribing Extended for Controlled Substances – News coverage of the DEA extension and its implications for telehealth access. Axios, November 18, 2024.

5. Hims to Cut 4% of Workforce Amid Ban on Weight Loss Drug Copies – Report on FDA’s ban on compounded semaglutide and its impact on telehealth companies. Reuters, May 30, 2025.

Verified as of: December 17, 2025
Note: Healthcare regulations evolve continuously. While this guide reflects current federal and state rules as of late 2025, always verify specific requirements with your telehealth provider and state medical board. The information provided is for educational purposes and does not constitute medical advice. Consult with a licensed healthcare provider to determine if GLP-1 therapy is appropriate for your individual situation.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid